By New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).
Study finds more polyarticular JIA patients achieve clinical remission with combined conventional and biologic DMARDs
Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk
Comments